Novel 5H-thiazolo[3,2-a]pyrimidin-5-one derivatives linked through an ethylene bridge to various phenylpiperazine groups were prepared for evaluation as 5-HT 2A receptor antagonists. The target compounds 11a-p were prepared through the initial synthesis of the 2-chloroethyl intermediates 10a-d which were then reacted with the appropriate phenylpiperazines. All compounds were tested for their antagonistic activity on 5-HT 2A receptors using inhibition of 5-hydroxytryptophan(5-HTP)-induced head twitches in mice. Pharmacophore modeling study, based on a hypothetical pharmacophore template generated from a set of diverse known active ligands, revealed good fitting of the designed compounds to the generated hypothetical pharmacophore. 
Introduction
Serotonin (5-hydroxytryptamine, 5-HT) has been recognized for more than 50 years as an effector on various smooth muscles and, subsequently, as an important neurotransmitter in the brain [1] . The serotonin receptors represent a diverse family 416 F. M. Awadallah: of receptors that has been initially classified pharmacologically into multiple subtypes [2] . The advent of molecular cloning provided additional discrimination within the serotonin receptor family revealing the existence of seven subfamilies containing a total of fourteen distinct receptors based on primary sequence, pharmacology and signal transduction pathways [1] . Serotonin receptor dysfunction has been implicated in many neuropsychiatric disorders including anxiety, depression and schizophrenia [1] . Clinical use of therapeutics affecting serotonergic function is exemplified by selective serotonin reuptake inhibitors for depression [2] , 5-HT 1A partial agonists for anxiety and depression, 5-HT 1D agonists for acute migraine [3] , 5-HT 2A and 5-HT 2C antagonists for migraine prophylaxis, depression, schizophrenia [4, 5] , 5-HT 3 antagonists for chemotherapy-induced emesis [6] , and 5-HT 4 agonists for gastrointestinal disorders [7] .
With particular emphasis on the 5-HT 2 receptor family, the three receptor subtypes, 5-HT 2A , 5-HT 2B and 5-HT 2C , are G-protein coupled receptors (GPCRs) that couple through the G q and G 11 proteins eliciting their second messenger effects through increases in activity of phospholipase C (diacylglycerol pathway) and/or phospholipase A (arachidonic acid pathway). These subtypes share an overall amino acid homology of approximately 50%. 5-HT 2A receptors are broadly distributed in the prefrontal, parietal, and somatosensory cortex, claustrum and in platelets [8] . The 5-HT 2A receptor has been implicated as a therapeutic target for schizophrenia and depression. Representative 5-HT 2A antagonists include ketanserin 1 [8] , the prototype of a large group of structurally related derivatives such as risperidone 2 [9] , and ritanserin 3 [10] . Other 5-HT 2A antagonists, belonging to different chemical classes, include the spiro compound, spiperone 4, the tricyclic derivative, clozapine 5, the indole derivative, sertindole 6 [11] , and the arylpiperazine derivative, aripiprazole 7 [12] (Chart 1).
Synthesis, Pharmacophore Modeling, and Biological Evaluation of Novel … enhances the antagonistic potency [11, 13] .
Inspired by this knowledge, the newly synthesized compounds were designed as structural mimics of ketanserin 1 and its analogs 2 and 3. The new compounds possessed an additional phenyl group on the thiazolopyrimidine nucleus, hoping to enhance the 5-HT 2A antagonistic activity. Moreover, the piperidine ring in the lead compounds was replaced by the isosteric piperazine ring with the aromatic substitution directly attached to it as in risperidone. The two carbon spacer (the ethylene bridge) was retained to keep the distance between the heterocyclic nucleus and the protonatable nitrogen (N 1 of the piperazine ring) as supported by the modeling study.
Results and Discussion

Chemistry
The target compounds 11a-p were prepared according to Scheme 1. The 2-aminothiazole derivatives 9a-d were obtained through a cyclocondensation reaction of the corresponding α-bromoacetophenones 8a-d [14] to thiourea according the reported procedures [15, 16] . Reaction of the appropriate 2-aminothiazole 9a-d, and 2-acetylbutyrolactone in phosphorous oxychloride furnished the 2-chloroethyl intermediates 10a-d. This was followed by alkylation of various phenylpiperazines with these intermediates in dry dimethylformamide in the presence of triethylamine under nitrogen atmosphere to give the final compounds 11a-p. 
11h R=Br R'=H 11p R=CH 3 R'=H Sch. 1.
Pharmacology
The new compounds were evaluated, in vivo, for their 5-HT 2A antagonistic activity by measuring their ability to inhibit the 5-HTP induced head twitches in mice [17, 18] . Risperidone was chosen as the standard drug. Risperidone was preferred over ritanserin as the standard drug, although the latter is more closely related to the tested compounds, because the former, unlike ritanserin, is widely marketed for clinical treatment of psychosis. The observed data were summarized in Tab 
Pharmacophore modeling
A molecular modeling experiment was carried out to develop a hypothetical pharmacophore model for the 5-HT 2A receptor aiming to study the fitting of the designed compounds to this pharmacophore. A ligand-based pharmacophore model was developed using a training set of ten 5-HT 2A antagonists of diverse chemical structures including compounds 1-6 (Chart 1), in addition to, setoperone, chlorpromazine, cyproheptadine, and tefludazine [11] . Fig. 1 shows the alignment of the ten selected structures. The generated hypothetical pharmacophore (Fig. 2) shows seven overlapping points with similar chemical properties in the training set, Pi orbitals properly oriented to fit to F2, F3 and F5. Also, N 1 of the piperazine ring is a H-bond acceptor corresponding to F1. The ethylene spacer is the hydrophobic group fitting to F6; it is worth mentioned that this 2 carbon spacer was perfect in adjusting the distance between other groups in the molecule. The thiazolopyrimidine ring is a suitable aromatic group for F4 with the nitrogen atom, at position 8, as a H-bond acceptor group for F7. Finally, it is interesting to note that, according to the created model, the phenyl group at position 3 is not part of the pharmacophore. Therefore, it will not be required to study the fitting of the rest of the compounds 11e-p since variations in the substituents on the 3-phenyl group will not affect the fitting results.
In conclusion, it could be assumed that the presence of the phenyl ring on the heterocyclic nucleus, although seeming not essential for activity as suggested by the molecular modeling study, yet the activity of the new compounds is in great part dependent on it. The role of the 3-phenyl group is unclear but it can be assumed that it fits into an accessory site of the receptor. Pharmacological data, supported by the modeling study, showed that the phenylpiperazine moiety is a suitable bioisostere of the arylpiperidine group present in ketanserin 1 and its analogs. In addition, the ethylene bridge is the proper spacer that keeps other groups in the molecule in the perfect position. 
Experimental
Chemistry
Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. Dimethylformamide (DMF) was dried over molecular sieve 4Ǻ. TLC was monitored on FLUKA silica gel TLC aluminium cards (0.2mm thickness) with fluorescent indicator 254 nm using chloroform:methanol given in ppm. Mass spectra were performed on Fennigan MAT, SSQ 7000 mass spectrophotometer at 70eV. IR spectra were recorded on Bruker FT-IR spectrophotometer as potassium bromide disc. Compounds 8a-d [14] , and 9a [15] , and 9b-d [16] were prepared according to the published procedures.
General procedure for the preparation of 6-(2-chloroethyl)-7-methyl-3-(un)substituted-phenyl-5H-thiazolo[3,2-a]pyrimidin-5-ones 10a-d:
A mixture of 9a-d (6 mmol) and 2-acetylbutyrolactone (0.65 ml, 6 mmol) in phosphorous oxychloride (15 ml) was heated under reflux for 2h. Excess phosphorous oxychloride was distilled under reduced pressure. The residue was triturated with ice-water and the suspension was neutralized with 2M ammonium hydroxide solution. The crude product was filtered, dried and crystallized from DMF-ethanol. A solution of compound 10a-d (2 mmol), the appropriate phenylpiperazine (2.1 mmol), and triethylamine (5 ml) in dry DMF (10 ml) was heated in a boiling water bath under nitrogen atmosphere for 10h. The solvent was removed under vacuum, and the residue was triturated with ice-water. The crude product was filtered, dried, and crystallized from the appropriate solvent. 
7-Methyl-3-phenyl-6-[2-(4-phenylpiperazin-1-yl)ethyl]-5H-thiazolo[3,2-
3-(4-Bromophenyl)-6-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one (11e):
Yield 35%; mp. 
3-(4-Bromophenyl)-7-methyl-6-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-
1-yl}ethyl)-5H-thiazolo[3,2-a]pyrimidin-5-one (11g):
Yield 32%; mp. 
3-(4-Bromophenyl)-7-methyl-6-[2-(4-phenylpiperazin-1-yl)ethyl]-5H-thiazolo[3,2-a]pyrimidin-5-one (11h):
Yield 46%; mp. 
Pharmacological screening
Inhibition of 5-HTP induced head twitches in mice.
The antagonism of 5-HT 2A receptors was determined in vivo by inhibition of 5-HTP induced head twitches in mice [18] . The animals were divided into seventeen groups each of six male mice (18-22g) Using the inhibition of 5-HTP induced head twitches in mice, the effects of the treatment with the new compounds on the dose-response% were graphically illustrated in comparison with that of risperidone (Fig. 7) .
The potencies (ED 50 ) of the tested compounds (Tab. 2), and statistical t-test for comparison between the potencies of the tested compounds and risperidone were performed by Prism 3 software.
Pharmacophore modeling study
All molecular modeling calculations were performed using "Molecular
Operating Environment (MOE) version 2007.09", Chemical Computing Group Inc., running on "Windows XP" operating system installed on an Intel Pentium IV PC with a 2.8 MHz processor and 512 RAM.
General methodology:
1-Alignment of the training set compounds:
The training set compounds, consisting of ten known 5-HT 2A antagonists of diverse chemical structure, were built using the builder interface of the MOE software. The compounds were aligned using the flexible alignment tool of the program adjusting the energy cut off to 10 kcal/mol and root mean square deviation (RMSD) tolerance to 0.5. The stochastic conformation search option was used as the method of alignment (Fig. 1) . 
2-Target compounds optimization:
Conformational analyses of the built molecules were performed in a two-step procedure. First, the target compounds were subjected to energy minimization tool using the included MOPAC 7.0. The geometry of the compounds was optimized with the semiemperical PM3 Hamiltonian using Restricted Hartree-Fock (RHF) and RMS gradient of 0.05 Kcal/mol. Then, the produced model was subjected to the 'Systematic Conformational Search' of the MOE. All items were set as default with RMS gradient of 0.01 Kcal/mol and RMS distance of 0.1 Ǻ. The obtained data were then saved as MBD file to be used in the pharmacophore fitting calculations.
3-Pharmacophore Building:
A pharmacophore model was created using the 'Pharmacophore Query
Editor'. The aligned training set compounds were used as the template for building the model. The settings of the software parameters were adjusted to:
'Unified' as the scheme of annotation 'Consensus method' for model building Tolerance was set to 1.2 Ǻ and the threshold was set to 50%.
The produced model was saved as *.ph file for testing compoundpharmacophore fitting and further calculations (Fig. 2) .
4-Fitting of the target compounds on the built model:
Using the generated pharmacophore model and the saved conformations of each molecule; the fitting of the target compounds 11a-d into the model was tested (Figs. 3-6 ). The root mean square deviation value for each conformer was calculated and the one having the lowest RMSD value was taken for further visual and energy inspection.
